On June 25, 2026, Definium Therapeutics, Inc., a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, closed its approximately US$805-million public offering, which included a full exercise of the underwriter’s option to purchase additional shares. J.P. Morgan, Jefferies, Leerink Partners and BofA Securities acted as the joint lead bookrunners for the offering, and Evercore ISI and Stifel acted as bookrunners for the offering. Oppenheimer & Co. and LifeSci Capital acted as co-lead managers for the offering.
Definium intends to use the net proceeds from this offering for the research and development of its product candidates, preparation activities for potential commercialization of DT120 ODT, if approved, and working capital and general corporate purposes.
Osler, Hoskin & Harcourt LLP acted as Canadian counsel to Definium with a team consisting of Trevor Scott, Minji Park, Julia McCarty, Hillary Song (Corporate), Kim Maguire and Xue Gao (Tax).
Key Contact
Partner, Corporate, Vancouver
Team
Partner, Corporate, Vancouver
Associate, Corporate, Vancouver
Associate, Corporate, Vancouver
Partner, Tax, Vancouver
Associate, Tax, Toronto
